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antiinflammatory drugs a#ect the progression of
osteoarthritis (OA) in humans. Most short-term
studies of patients with OA are directed at the
relief of symptoms and based on clinical measure-
ments of changes in pain and/or function. The
relief of pain is indeed the ultimate goal of any
drug used in a frequent condition like OA.
As the evolution is slow and as the variability
of the clinical status of OA patients is large,
radiological assessment of a#ected joints seems
to constitute an objective means for long-term
evaluation. The most frequently measured par-
ameters are the joint space (in order to assess the
joint-space narrowing) and the size of osteophytes.
The European Group for the Respect of Ethics
and Excellence in Science (GREES) recommenda-
tions for governmental registration and approval
of drugs used in the treatment of OA have added
the requirement that the drug not have a deleteri-
ous e#ect on the non-diseased contralateral joint;
i.e., no deleterious e#ect on normal cartilage [1].
In animal models, it is methodologically con-
venient to demonstrate changes in the mechanical
structure of cartilage. Several studies have
shown a protective e#ect of several compounds on
cartilage structure and on osteophyte progression
[2, 3]. In the study of Williams and Brandt [2],
benoxaprofen was shown not only to impair the
development of osteophytes, but also to have
potentially adverse e#ects on the normal cartilage,
thus emphasizing the relevance of the GREES
requirements [1].
The reproducibility of the radiological evalu-
ation seems to be good enough to determine the
changes with time and discriminate any therapeu-
tic e#ect of drugs in groups of patients. This is
particularly true when special techniques are used
[5].
In most studies of OA (except for rapidly pro-
gressive OA), there is an inverse relationship
between the progressive narrowing of joint space336and osteophyte size. Osteophyte size increased
significantly in the placebo-treated groups [5, 6]. In
most studies using conventional X-rays, there was
a non-significant trend to a slower progression of
OA in the NSAID-treated group, as compared to
the placebo group [6, 7]. However, the amount of
bone reaction seen on the radiograph varies
enormously as OA progresses. Solomon et al. have
suggested to divide OA into hypertrophic and
atrophic categories [8]. The osteophyte size is only
increased in hypertrophic OA. A distinction
should also be made between age-related small
osteophytes at the joint margins producing some
degree of squaring at the joint margin and OA
osteophytes which are much larger. The exact role
played by marginal osteophytes on reduction of
varus-valgus instability in osteoarthritic knees is
still unclear [9].
A therapeutic intervention aiming at blocking
osteophyte development could therefore not be
wise in every case. However, in most cases, the
prevention of joint destruction will be paralleled
with a smaller development of osteophytes.
Several nonsteroidal antiinflammatory drugs,
benoxaprofen as well as intraarticular triamci-
nolone have been shown to dramatically reduce
the number and size of osteophytes, both in animal
and in human studies. The therapeutic e#ect on
osteophytes can therefore be used as a means for
assessing the e#ects of therapeutic intervention onReferences
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